Celcuity reports updated gedatolisib clinical results in metastatic castration-resistant prostate cancer

Celcuity reported updated clinical results from its Phase 1b/2 study of gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer, presented at the 2026 ESMO Congress. Median radiographic progression-free survival was 15.7 months for patients with prior abiraterone exposure and 9.1 months for those with prior enzalutamide exposure.

Detected & updated continuously · Source: Nebula